• Market Capitalisation market-capitalisation-info $4,663 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-60 Mln

Vaxcyte Inc. (PCVX) Share Price

$50.08

As on 28-Nov-2023 16:00 EST

up-down-arrow $-0.05-0.10%

  • Prev Close info

    $50.13

  • Day's Openinfo

    $49.22

  • Today's Highinfo

    $50.16

  • Today's Lowinfo

    $48.81

  • Today's Volumeinfo

    443,270

  • 52 Week rangeinfo

    $34.11 - 54.97

Please wait...

Vaxcyte Inc. (PCVX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Vaxcyte (PCVX)
4.44 6.55 0.12 13.82 13.07 -- --
S&P BSE Sensex*
10.91 5.65 4.09 6.94 15.19 13.27 12.49
S&P Small-Cap 600#
-5.82 -5.34 -13.90 -6.30 5.30 2.98 5.53
As on 28-Nov-2023  |  *As on 01-Dec-2023  |  #As on 26-Oct-2023
2022
2021
Vaxcyte (PCVX)
101.56 -10.46
S&P Small-Cap 600
-17.42 25.27
S&P BSE Sensex
4.44 21.99

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Vaxcyte Inc. (PCVX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Vaxcyte Inc. (PCVX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Vaxcyte Inc. (PCVX)

        Co-Founder, CEO & Director

        Mr. Grant E. Pickering M.B.A.

        Pres, CFO & Principal Accounting Officer

        Mr. Andrew L. Guggenhime M.B.A.

        Headquarters

        San Carlos, CA

        FAQs for Vaxcyte Inc. (PCVX)

        The total asset value of Vaxcyte Inc. (PCVX) stood at $ 1,582 Mln as on 30-Sep-23

        The share price of Vaxcyte Inc. (PCVX) is $50.08 (NASDAQ) as of 28-Nov-2023 16:00 EST. Vaxcyte Inc. (PCVX) has given a return of 13.07% in the last 3 years.

        Vaxcyte Inc. (PCVX) has a market capitalisation of $ 4,663 Mln as on 24-Nov-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Vaxcyte Inc. (PCVX) is 10.05 times as on 24-Nov-2023, a 2.96% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Vaxcyte Inc. (PCVX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Vaxcyte Inc. (PCVX) and enter the required number of quantities and click on buy to purchase the shares of Vaxcyte Inc. (PCVX).

        Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

        The CEO & director of Mr. Grant E. Pickering M.B.A.. is Vaxcyte Inc. (PCVX), and CFO & Sr. VP is Mr. Andrew L. Guggenhime M.B.A..

        The promoters of Vaxcyte Inc. (PCVX) have pledged 0% of the total equity as on Jun-23.

        Vaxcyte Inc. (PCVX) Ratios
        Return on equity(%)
        -25.8
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Vaxcyte Inc. (PCVX) was $-60 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $4,662.54 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-60.46 Mln
        • Cash date-information $1,265.68 Mln
        • Total Debt info $13.81 Mln
        • Insider's Holding 3.44%
        • Liquidity liquidity High
        • 52 Week range week-range $34.11 - 54.97
        • Shares outstanding share-outstanding 95,153,904
        • 6 Years Aggregate:

          CFO: $-431.19 Mln

          EBITDA: $-452.20 Mln

          Net Profit: $-527.77 Mln

        About The Company

        • IPO Date 12-Jun-2020
        • Co-Founder, CEO & Director Mr. Grant E. Pickering M.B.A.
        • Pres, CFO & Principal Accounting Officer Mr. Andrew L. Guggenhime M.B.A.
        • Listing key-listing NASDAQ: PCVX
        • Country United States
        • Headquarters headquarters San Carlos, CA
        • Website website https://vaxcyte.com
        • Business

          Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the...  prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon